Clinical trial · Interventional
Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
NCT01368419CI-TRIAL-00010127unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to explore the clinical efficacy of continuous Endostar infusion combined with radiotherapy in esophageal cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endostar | Drug | — | UNRESOLVED |
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment
- interventionNames
- Drug: Endostar
- Radiation: Radiotherapy
Primary outcomes (1)
- measure
- Objective Response Rate (ORR)
- timeFrame
- 1 month after treatment
Secondary outcomes (5)
- measure
- Overall Survival (OS)
- timeFrame
- 2 years
- measure
- Time to Progression (TTP)
- timeFrame
- every three months until disease progression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological diagnosis of previously untreated stage I-III esophageal cancer * Measurable disease according to RECIST criteria * ECOG Performance Status 0-1 * The length of esophageal carcinoma ≤ 10 cm * Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 90g/L * Renal function: Cr ≤ 2.0×UNL * Hepatic function: BIL ≤ 2.0×UNL, ALT/AST ≤ 5.0×UNL Exclusion Criteria: * Pregnant or lactating women * Evidence of bleeding diathesis, serious infection * Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension) * Uncontrollable mental and nervous disorders
References
Publications (0)
Data not yet available
No reference posted for this study.